Samsung Bioepis plans to start a global Phase 1 trial of SBE303, its first independently developed new drug candidate targeting Nectin-4. Preclinical data showed tolerability up to 40 mg/kg in monkeys.
The liposomal doxorubicin market is projected to grow from $1.32 billion in 2025 to $1.77 billion by 2030, while the broader breast cancer drugs market is expected to reach $54.49 billion by 2036. Growth is driven by increasing cancer incidence, adoption of targeted therapies, and advancements in drug delivery systems including liposomal formulations and antibody-drug conjugates.
GSK's antibody-drug conjugate risvutatug rezetecan has received Orphan Drug Designation in Japan for small-cell lung cancer, marking its sixth global regulatory designation. The decision was based on phase I trial data showing durable responses in extensive-stage SCLC patients. The drug is currently in phase III development for relapsed ES-SCLC.
Grail's NHS-Galleri trial of 142,000 participants failed to achieve statistically significant reduction in late-stage cancer diagnoses, though secondary endpoints showed four-fold improvement in overall cancer detection rate. Stock fell 48% following the announcement.
New research warns AI pathology systems may use statistical shortcuts rather than biological signals, while a clinical trial shows stereotactic radiation improves quality of life for patients with multiple brain metastases compared to whole brain radiation.
New research demonstrates that physical activity after cancer diagnosis reduces mortality risk in less common cancers and enhances circadian clock function in tumor tissue, supporting exercise as a therapeutic intervention.
Novartis announced plans to establish a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion US expansion. The facility is expected to be operational in 2028.
Early trial of Rezatapopt shows 20% response rate in advanced cancers with p53 mutations, while researchers identify AMD3100 as potential solution to enable immunotherapy in rare liver cancer.
The global oncology precision medicine market is projected to grow from $190.50 billion in 2026 to $366.53 billion by 2033 at a 9.8% CAGR, while the cancer biomarker testing market is expected to reach $96.53 billion by 2033 at a 12.6% CAGR.
Vir Biotechnology announced a global strategic collaboration with Astellas for VIR-5500, a PSMA-targeted dual-masked T-cell engager for prostate cancer, and reported $781.6 million in cash and investments as of December 31, 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07583550 |
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07505589 |
Pacing In Organ Donors (the POD Trial) |
COMPLETED | NA |
| NCT07057804 |
Lung and Diaphragm Ultrasound in Predicting Extubation and Weaning of Mechanically Ventilated Patients in Intensive Care Unit |
COMPLETED | |
| NCT07057531 |
Tubeless VATS for Lung Cancer Surgery |
COMPLETED | NA |
| NCT06957600 |
The Comparison of Navigational Bronchoscopic and CT-Guided Preoperative Markings in Minimally Invasive Thoracic Surgery |
COMPLETED | NA |
| NCT06843707 |
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics. |
RECRUITING | |
| NCT06815198 |
Pulsed Eco Doppler for Polmonal Discharge Velocity |
RECRUITING | |
| NCT06778512 |
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer |
RECRUITING | |
| NCT06602661 |
Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy |
NOT_YET_RECRUITING | PHASE1 |
| NCT06115395 |
Non-invasive Ventilation Assisted Fiber-optic Bronchoscopy |
RECRUITING | NA |
